Tirzepatide, an FDA-approved drug for type 2 diabetes , was found to help achieve blood sugar control and weight loss goals faster than some other diabetes medications. The SURPASS trials evaluated the effect of different doses of injectable tirzepatide on blood sugar levels. Adults treated with 5, 10, and 15 mg of tirzepatide reached blood glucose targets in about four weeks sooner than those treated with 1 mg of injectable semaglutide, and 4–12 weeks sooner than those treated with once-daily insulin. The drug has been found to achieve weight loss goals faster too.
It took an average of 12 weeks to lose at least 5% of body weight, whereas semaglutide took 24 weeks. Tirzepatide mimics two natural hormones, namely glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) , which are involved in blood sugar regulation and appetite reduction. However, the…
